Drug intelligence / Profile preview

Biovascular Lung

Development stage: Preclinical
Lead developer: Humacyte
Modality: Cell Therapies
Administration: Implant

Overview

Biovascular Lung is a preclinical-stage tissue-engineered organ system being developed by Humacyte for the treatment of lung diseases. The program utilizes Humacyte's proprietary regenerative medicine platform to create bioengineered lung tissue intended to restore or replace respiratory function. The process typically involves seeding human cells onto a biodegradable scaffold within a bioreactor to generate a complex extracellular matrix, which is then decellularized to produce a non-immunogenic, off-the-shelf tissue scaffold that can be integrated into the patient's physiology.

Other names: Biovascular Lung

Beyond the preview

Go deeper on Biovascular Lung.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Biovascular Lung.

Explore the full profile